house Bill H.R. 1520
Should the FDA’s ‘Purple Book’ of Biosimilar Products Be More Useful for Developers of Generics?
Argument in favor
Biosimilars are becoming increasingly important as a mode of treatment for a range of conditions. However, branded products can be expensive — so supporting generic biosimilar development through resources such as the Purple Book is important.
05/08/2019
Anything to cut healthcare prices whilst on the way to a universal single payer healthcare system.
05/08/2019
Good decision this position seems reasonable and responsible and thanks to my representative who voted affirmatively.
05/08/2019
I cannot see how passing this and providing competition in biosimilars would lessen innovation. Competition inspires companies to create a better widget and think outside the box. This is the lamest excuse I have heard in a long time and is appalling coming from Republicans as it seems like a way to protect special interests.
Healthcare needs to be less expensive. I believe this will be part of achieving that goal.
Argument opposed
While lowering drug prices for consumers through generics, including for biosimilar medical products, this bill could stifle innovation by empowering generic manufacturers relative to the initial developer.
···
05/09/2019
If this is anything like the slippery slope of FDA approval for medical devices that get grandfathered in based on its similarities to previous devices then NO. Everyone should watch the documentary The Bleeding Edge to see what an enormous mistake that is.
···
05/08/2019
Sound like the FDA would be required to do the leg work for many would be generic drug manufacturers under this Bill. That’s not the job the FDA should devote resources to.
···
05/08/2019
"Generic" medications are helpful, but the system works, as it is. FDA meddling, like most government interference, cause much more harm, and almost no help.
Anything to cut healthcare prices whilst on the way to a universal single payer healthcare system.
If this is anything like the slippery slope of FDA approval for medical devices that get grandfathered in based on its similarities to previous devices then NO. Everyone should watch the documentary The Bleeding Edge to see what an enormous mistake that is.
Good decision this position seems reasonable and responsible and thanks to my representative who voted affirmatively.
I cannot see how passing this and providing competition in biosimilars would lessen innovation. Competition inspires companies to create a better widget and think outside the box. This is the lamest excuse I have heard in a long time and is appalling coming from Republicans as it seems like a way to protect special interests.
Healthcare needs to be less expensive. I believe this will be part of achieving that goal.
Good to use purple book for development of more generics in prescription drugs.
"Generic" medications are helpful, but the system works, as it is. FDA meddling, like most government interference, cause much more harm, and almost no help.
Sound like the FDA would be required to do the leg work for many would be generic drug manufacturers under this Bill. That’s not the job the FDA should devote resources to.
Pharmaceutical companies are using government research grants and funds to create these drugs. Profits should be passed on to the consumer as soon as possible.
Thank you. As a person with chronic pain It is debilitating when I'm in pain and I cannot get meds because the pharmacy doesn't cover the genetic formulary!
While lowering drug prices for consumers through generics, including for biosimilar medical products, this bill could stifle innovation by empowering generic manufacturers relative to the initial developer.
This would give better competition for lower prices against the big companies.
This sounds like a socialist program to take way the hard work of one company and to give it to another. I do not want companies that are not willing to pay or do their own research selling drugs because who knows what else they might not do.
Short of a complete overhaul of the FDA certification process, this seems like a useful tool to help manufacturers navigate the existing bureaucracy.
The Generics industry as a whole should be subject to far more rigor. We have large labs in China and India controlling huge swaths of drug classes ( antidepressants) with little regard for actual efficacy. This really requires more scientific proof of efficacy and not less.
We must take a stand to lower the price of medicine and healthcare
Of course Big Pharma will be against this. Now we'll see how many of our representatives are influenced by them.
When one can not get a generic medication, many will do without the RX because it is too expensive. It seems this would be something that “the people” you represent really need! Please vote yes!